Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab intensification and maintenance after R-CHOP14 for diffuse large B-cell lymphoma
NL-OMON47490Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by HOVON. Primary endpoints: Response rate and Failure-free survival. Started Oct 2007; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON47490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47490.